Naldemedine

From WikiMD's Wellness Encyclopedia

(Redirected from Naldemedine tosylate)

What is Naldemedine?[edit | edit source]

  • Naldemedine (Symproic) is an opioid antagonist used for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Naldemedine
Error creating thumbnail:
Naldemedine structure



What are the uses of this medicine?[edit | edit source]

  • Naldemedine (Symproic) is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids in adults with long-lasting (chronic) pain that is not caused by active cancer.


How does this medicine work?[edit | edit source]

  • Naldemedine (nal dem' e deen) is a semisynthetic opiate receptor antagonist which is similar structurally to naltrexone and blocks mu receptors in the enteric nervous system of the gastrointestinal tract resulting in an inhibition of opioid induced slowing of peristalsis.
  • Naldemedine has a large polar side chain that does not block its engagement with opioid receptors, but does prevent it from crossing the blood brain barrier.
  • As a consequence, naldemedine reverses the peripheral but not the central nervous system effects of opiates, such as pain relief and euphoria.
  • In large preregistration trials, naldemedine was found to increase spontaneous bowel movement frequency and reduce constipation related side effects of opiates used for analgesia in patients with chronic, non-cancer pain.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients who:

  • have a bowel blockage (intestinal obstruction) or have a history of bowel blockage.
  • are allergic to Symproic or any of the ingredients.


What drug interactions can this medicine cause?[edit | edit source]

  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Be sure to mention any of the following:


Is this medicine FDA approved?[edit | edit source]

  • Naldemedine was approved for this use in the United States in 2017 and is currently available as tablets of 0.2 mg under the brand name Symproic.


How should this medicine be used?[edit | edit source]

Recommended dosage:

  • The recommended dosage of Symproic is 0.2 mg orally once daily with or without food.

Administration:

  • Naldemedine comes as a tablet to take by mouth.
  • Take Symproic exactly as your healthcare provider tells you to take it.
  • Take your prescribed dose of Symproic 1 time each day.
  • Symproic can be taken with or without food.
  • Symproic has been shown to be effective in people who have taken opioid pain medicines for at least 4 weeks.
  • Tell your healthcare provider if you stop taking your opioid pain medicine. If you stop taking your opioid pain medicine, you should also stop taking Symproic.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Tablets: 0.2 mg naldemedine

This medicine is available in fallowing brand namesː

  • Symproic


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

Symproic may cause serious side effects, including:


What special precautions should I follow?[edit | edit source]

  • Cases of gastrointestinal perforation have been reported with use of another peripherally acting opioid antagonist in patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract. Consider the overall risk benefit in patients with known or suspected lesions of the GI tract. Monitor for severe, persistent, or worsening abdominal pain; discontinue if development of symptoms.
  • Clusters of symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing, feeling cold, abdominal pain, diarrhea, nausea, and vomiting have occurred in patients treated with Symproic. Consider the overall risk benefit in patients with disruptions to the blood-brain barrier. Monitor symptoms of opioid withdrawal.
  • Advise patients to discontinue Symproic if treatment with the opioid pain medication is also discontinued.
  • Advise females of reproductive potential, who become pregnant or are planning to become pregnant, that the use of Symproic during pregnancy may precipitate opioid withdrawal in a fetus due to the undeveloped blood-brain barrier.
  • Advise women that breastfeeding is not recommended during treatment with Symproic and for 3 days after the final dose.
  • Naldemedine has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.


What to do in case of emergency/overdose?[edit | edit source]

Symptoms of overdosage may include:

  • Dose-dependent increases in gastrointestinal-related adverse reactions, including abdominal pain, diarrhea, nausea, and vomiting, were observed.
  • Also, chills, hyperhidrosis, and dizziness were reported.

Management of overdosage:

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
  • Overdose related information is also available online at poisonhelp.org/help.
  • In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
  • No antidote for naldemedine is known.
  • Hemodialysis is not an effective means to remove naldemedine from the blood


Can this medicine be used in pregnancy?[edit | edit source]

  • There are no available data with naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
  • Taking Symproic during pregnancy may cause opioid withdrawal symptoms in your unborn baby.
  • Tell your healthcare provider right away if you become pregnant during treatment with Symproic.
  • Symproic should be used during pregnancy only if the potential benefit justifies the potential risk.


Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of Symproic have not been established in pediatric patients.


What are the active and inactive ingredients in this medicine?[edit | edit source]

  • Active Ingredient: naldemedine tosylate
  • Inactive ingredients: D-mannitol, croscarmellose sodium, magnesium stearate, hypromellose, talc, and yellow ferric oxide.


Who manufactures and distributes this medicine?[edit | edit source]


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store Symproic at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep Symproic in the bottle that it comes in.


Antidiarrheal agents[edit source]

Antidiarrheal agents include bulk forming agents, hydroscopic agents, bile acid resins, bismuth, inhibitors of intestinal motility, non-absorbed antibiotics and hormones. Bulk forming agents include methylcellulose; hydroscopic agents include pectin and kaolin; bile acid resins are cholestyramine, colestipol and colesevalam; inhibitors of intestinal motility include opioids such as diphenoxylate and loperamide. Antibiotics include rifamycin and rifaximin which are non-absorbed and are used for travelers' diarrhea. Hormones with antidiarrheal activity include octretide and somatostatin. Most antidiarrheal agents are active locally in the small intestine and colon and are largely not absorbed. Some, however, have been implicated in rare causes of liver injury (senna, cascara, cholestyramine). Telotristat is a relatively new agent that inhibits the synthesis of serotonin and is used specifically for the diarrhea of carcinoid syndrome.

Antiemetics are a diverse group of medications that act at different points in the pathways that regulate nausea and vomiting. These include antihistamines, anticholinergic agents, phenothiazines, serotonin type 3 receptor blockers, centrally acting benzamides, cannabinoid receptor agonists, substance P antagonists and miscellaneous.

Anticholinergic Agents

Antihistamines

Cannabinoid Receptor Agonists

Serotonin 5-HT3 Receptor Antagonists

Substance P/Neurokinin 1 Receptor Antagonists

Miscellaneous

Acid peptic disease/antiulcer agents that include antacids, the histamine type 2 receptor blockers (H2 blockers), and the proton pump inhibitors (PPIs). These agents are some of the most commonly taken medications and are very well tolerated, most being available both by prescription and over-the-counter. While many of these drugs are approved for use in duodenal and gastric ulcer disease, their major use is for acid reflux and indigestion.

Histamine H2 Receptor Antagonists (H2 Blockers) Cimetidine, Famotidine, Nizatidine, Ranitidine

Proton Pump Inhibitors

Cathartics, laxatives or agents for constipation include bulk forming agents, osmotic agents, stool wetting agents, nonspecific stimulants, prokinetic agents and agents that increase fluid secretion. Many of these therapies are not systemically absorbed and none are considered particularly hepatotoxic. Naldemedine and naloxegol are opioid antagonists and are used to treat the constipation associated with opioid use.

Inflammatory bowel disease encompasses several disorders, most commonly ulcerative colitis and Crohn colitis. Agents can be classified as 5-aminosalicyclic acid (5-ASA) based agents, immunosuppressive drugs, antitumor necrosis factor agents, corticosteroids, antibiotics and miscellaneous.

5-Aminosalicyclic Acid (5-ASA) Derivatives

Immunosuppressive Agents

Tumor Necrosis Factor Antagonists

Miscellaneous

Irritable Bowel Syndrome Agents Antimuscarinics/Antispasmodics [See Anticholinergic agents

Prokinetic Agents - See Serotonin 5-ht4 receptor agonists Alosetron, Cisapride, Domperidone, Linaclotide, Lubiprostone, Metoclopramide, Plecanatide, Prucalopride, Tegaserod

Other

Naldemedine Resources



Retrieved from "https://wikimd.com/w/index.php?title=Naldemedine&oldid=4956772"

Contributors: Deepika vegiraju